WallFlex Biliary Fully Covered (FC) Benign Stricture Study
A Multi-Center, Prospective Study of the WallFlex Biliary RX Fully Covered Stent for the Treatment of Benign Biliary Strictures
Sponsor: Boston Scientific Corporation
This PHASE3 trial investigates Biliary Stricture and is currently completed. Boston Scientific Corporation leads this study, which shows 11 recorded versions since 2009 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE3
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE3
▶ Show 6 earlier versions
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE3
-
Mar 2020 — Jan 2021 [monthly]
Completed PHASE3
Status: Unknown Status → Completed
-
Jul 2018 — Mar 2020 [monthly]
Unknown Status PHASE3
Status: Active Not Recruiting → Unknown Status
-
Jun 2018 — Jul 2018 [monthly]
Active Not Recruiting PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Dec 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Boston Scientific Corporation
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Brussels, Belgium , Düsseldorf, Germany , Girona, Spain , Hyderabad, India , Lyon, France , Montreal, Canada , Rome, Italy , Rotterdam, Netherlands , Santiago, Chile , Toronto, Canada and 2 more locations